title: Reply to L. Casadaban et al.
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Donna
authors.initials: D
authors.lastname: Niedzwiecki
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Wendy L
authors.initials: WL
authors.lastname: Frankel
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Alan P
authors.initials: AP
authors.lastname: Venook
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Xing
authors.initials: X
authors.lastname: Ye
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Paula N
authors.initials: PN
authors.lastname: Friedman
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Richard M
authors.initials: RM
authors.lastname: Goldberg
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Mayer
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Colacchio
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Jude Marie
authors.initials: JM
authors.lastname: Mulligan
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Timothy S
authors.initials: TS
authors.lastname: Davison
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Eamonn
authors.initials: E
authors.lastname: O'Brien
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Peter
authors.initials: P
authors.lastname: Kerr
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Patrick G
authors.initials: PG
authors.lastname: Johnston
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Richard D
authors.initials: RD
authors.lastname: Kennedy
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: D Paul
authors.initials: DP
authors.lastname: Harkin
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Richard L
authors.initials: RL
authors.lastname: Schilsky
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Monica M
authors.initials: MM
authors.lastname: Bertagnolli
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Warren
authors.affiliation: Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Federico
authors.initials: F
authors.lastname: Innocenti
mesh_terms: D003110:Colonic Neoplasms; D006801:Humans; D009364:Neoplasm Recurrence, Local; D059467:Transcriptome